{"protocolSection":{"identificationModule":{"nctId":"NCT06480955","orgStudyIdInfo":{"id":"BOREALIS_CIPv1.0"},"organization":{"fullName":"Cardiovascular and Interventional Radiological Society of Europe","class":"OTHER"},"briefTitle":"BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe","officialTitle":"BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe","acronym":"BOREALIS"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-11","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-19","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Cardiovascular and Interventional Radiological Society of Europe","class":"OTHER"},"collaborators":[{"name":"Boston Scientific Corporation","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":true,"isUsExport":false},"descriptionModule":{"briefSummary":"BOREALIS is a multicentre, prospective, observational cohort study designed to investigate the effectiveness, feasibility, safety and impact on pain and quality of life of curative-intent cryoablation for the treatment of bone metastases in patients with oligometastatic or bone oligo-progressive disease."},"conditionsModule":{"conditions":["Bone Metastases"],"keywords":["Cryoablation Oligo-progressive disease","Bone metastases","Oligometastatic Disease","Oligo-progressive disease"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"1 Year","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":50,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Full cohort","description":"Cryoablation with curative-intent of bone metastases from oligometastatic or bone oligo-progressive disease.","interventionNames":["Device: Cryoablation system"]}],"interventions":[{"type":"DEVICE","name":"Cryoablation system","description":"Any cryoablation system from Boston Scientific that has received CE Mark and/or FDA clearance for the ablation of bone malignancies.","armGroupLabels":["Full cohort"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Local progression-free survival rate","description":"On a per lesion basis, proportion of target lesions free from local tumour progression using the Kaplan Meier estimate","timeFrame":"12 months"}],"secondaryOutcomes":[{"measure":"Technical feasibility","description":"Adherence to a comprehensive SOC treatment protocol that includes i) peri-operative biopsy if indicated, ii) cryoablation, and iii) bone consolidation through osteoplasty or osteosynthesis if biomechanically indicated","timeFrame":"Periprocedurally"},{"measure":"Adverse events","description":"Incidence and severity of adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","timeFrame":"Through study completion"},{"measure":"Complete local tumour response","description":"On a per lesion basis, proportion of target lesions with complete response status","timeFrame":"12 months"},{"measure":"Fracture-free survival","description":"On a per lesion basis,time between cryoablation and fracture at treated site","timeFrame":"End of study"},{"measure":"Fracture-free survival rate","description":"On a per lesion basis, proportion of target lesion(s) free from fracture","timeFrame":"Until the end of the follow-up period (1 year)"},{"measure":"Bone-disease progression-free survival","description":"Time between cryoablation and progression in the bone (incl. new lesions)","timeFrame":"Until the end of the follow-up period (1 year)"},{"measure":"Extraosseous disease progression-free survival","description":"Time between cryoablation and extra-osseous progression (incl. new lesions)","timeFrame":"Until the end of the follow-up period (1 year)"},{"measure":"Overall progression-free survival","description":"Time between cryoablation and any progression (incl. new lesions) or death","timeFrame":"Until the end of the follow-up period (1 year)"},{"measure":"Overall survival","description":"Time between cryoablation and death","timeFrame":"Until the end of the follow-up period (1 year)"},{"measure":"Systemic therapy-free survival","description":"Time between cryoablation and the next systemic treatment (excluding any adjuvant treatment that was part of the patient's treatment plan)","timeFrame":"Until the end of the follow-up period (1 year)"},{"measure":"Impact on patient pain","description":"Patient-reported pain assessment using the Brief Pain Inventory - short form","timeFrame":"1, 3, 6, 12 months"},{"measure":"Impact on patient quality of life","description":"Patient-reported quality of life assessment using the EORTC QLQ-C30 questionnaire","timeFrame":"1, 3, 6, 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Bone metastases in patients with oligometastatic disease (\\<5 bone/visceral metastases) or bone oligo-progressive disease (visceral or osseous multi-metastatic disease stable under systemic treatment except 1-3 progressing bone metastases) from solid tumours;\n* Number of target lesions â‰¤ 3\n* Size of target lesion(s) \\< 5 cm (largest diameter);\n* Referral to local ablative treatment by multidisciplinary tumour board (MDTB);\n* Treatment by percutaneous cryoablation with curative intent (i.e., complete tumour destruction) assessed as technically feasible by the IR in charge;\n* Procedure performed with a cryoablation system from Boston Scientific.\n\nExclusion Criteria:\n\n* \\< 18 years old;\n* Incapacity or refusal to give informed consent;\n* Ongoing pregnancy;\n* Health status not compatible with the minimum meaningful follow-up period (i.e., 12 months):\n\n  * Karnofsky Performance Scale \\< 60%, or\n  * Bone metastases originating from rapidly evolving tumour histologies not allowing reasonable life expectancy of at least 12 months, or\n  * Life expectancy \\< 12 months\n* Infection of treatment site or systemic infection;\n* Uncorrectable coagulopathy;\n* Haematological disease (including multiple myeloma and plasmacytoma);\n* Concomitant radiation therapy or radiation therapy within 12 weeks before the planned cryoablation procedure.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with bone metastases from oligometastatic or bone oligo-progressing disease from solid tumours treated with curative-intent cryoablation may participate in BOREALIS. Patients from vulnerable populations (e.g., minors, pregnant women, incapacitated or unconscious individuals) shall not be included in the study.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Claire E Poulet, PhD","role":"CONTACT","phone":"+43 1904 2003 71","email":"borealis@cirse.org"}],"overallOfficials":[{"name":"Roberto L Cazzato, Dr","affiliation":"Strasbourg University Hospitals, Strasbourg, France","role":"STUDY_CHAIR"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000009362","term":"Neoplasm Metastasis"},{"id":"D000001859","term":"Bone Neoplasms"},{"id":"D000001855","term":"Bone Marrow Diseases"}],"ancestors":[{"id":"D000009385","term":"Neoplastic Processes"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000001847","term":"Bone Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000006402","term":"Hematologic Diseases"}],"browseLeaves":[{"id":"M12307","name":"Neoplasm Metastasis","asFound":"Metastases","relevance":"HIGH"},{"id":"M20559","name":"Disease Progression","relevance":"LOW"},{"id":"M5138","name":"Bone Neoplasms","asFound":"Bone Metastases","relevance":"HIGH"},{"id":"M5134","name":"Bone Marrow Diseases","asFound":"Bone Metastases","relevance":"HIGH"},{"id":"M12330","name":"Neoplastic Processes","relevance":"LOW"},{"id":"M5126","name":"Bone Diseases","relevance":"LOW"},{"id":"M12097","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"}]}},"hasResults":false}